Stockscreener 앱 받기
1.69
6.11%
-0.11
전일 마감가:
$1.80
열려 있는:
$1.79
하루 거래량:
152.06K
Relative Volume:
0.14
시가총액:
$9.18M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+2.42%
1개월 성능:
+38.52%
6개월 성능:
-63.66%
1년 성능:
-89.21%
1일 변동 폭
$1.67
$1.79
1주일 범위
$1.60
$1.95
52주 변동 폭
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
TRAW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.69 | 9.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Millennium Management LLC Buys New Holdings in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer - MSN
Traws Pharma (NASDAQ:TRAW) Trading 0.6% Higher – Here’s What Happened - Defense World
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MSN
Traws Pharma Inc. Stock Skyrockets Over 40%, Then Pares Gains in Volatile Trading - Daily Chhattisgarh News
Traws Pharma Stock (TRAW) Surges 55% on Positive Cancer Data - TipRanks
Traws Pharma (TRAW) Releases Promising Clinical Trial Results fo - GuruFocus
Traws Pharma Publishes Promising Phase 2 Study Results - TipRanks
Traws Pharma Announces Publication of Compelling Efficacy - GlobeNewswire
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - GlobeNewswire Inc.
Traws Pharma Receives FDA Feedback on Flu Drug Development - MSN
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir - GlobeNewswire
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - marketscreener.com
Traws Pharma advances flu drug development with FDA feedback - Investing.com India
Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness - marketscreener.com
Traws Pharma Receives FDA Guidance on Flu Treatment - TipRanks
Traws Pharma (TRAW) Gains FDA Insights on Flu Treatment Pathway | TRAW Stock News - GuruFocus
Traws Pharma advances flu drug development with FDA feedback By Investing.com - Investing.com Nigeria
FDA Advances Critical Bird Flu Drug Development as Ex-CDC Chief Warns of 50% Death Rate Risk - Stock Titan
Traws Pharma Unveils New Strategic Antiviral Focus - TipRanks
Traws Pharma’s Q1 2025 Results Highlight Progress and Profit - TipRanks
Traws Pharma Reports First Quarter 2025 Results And Business Highlights - marketscreener.com
Traws Pharma Reports Q1 2025 Financial Results - TipRanks
Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewswire
Traws Pharma Earnings Surge to $21.5M as Former CDC Director Backs Novel Flu and COVID Drug Pipeline - Stock Titan
Renaissance Technologies LLC Takes $89,000 Position in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Geode Capital Management LLC Makes New $185,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
TRAW stock touches 52-week low at $1.51 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $1.51 amid sharp annual decline - Investing.com India
Traws Pharma Appoints New Chairman Amid Leadership Changes - MSN
Traws Pharma appoints new interim CEO with compensation details By Investing.com - Investing.com Canada
Traws Pharma appoints new interim CEO with compensation details - Investing.com Australia
Traws Pharma announces $50 million stock offering potential - Investing.com Australia
Traws Pharma announces $50 million stock offering potential By Investing.com - Investing.com Canada
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Traws Pharma Inc (TRAW) 재무 분석
Traws Pharma Inc (TRAW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):